Memantine Ariti (Memantine Hydrochloride)

Memantine works by blocking the NMDA receptor’s ion channel in a non‑competitive manner. This reduces excessive calcium influx caused by over‑activation of glutamate, limiting excitotoxic neuronal damage while allowing normal neurotransmission to continue.

The specific dose and titration schedule for Memantine Ariti are determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of memantine in pregnancy and lactation has not been established. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas cholinesterase inhibitors such as donepezil act by increasing acetylcholine levels. Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit, offering a different mechanism of action.

Memantine Ariti should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Memantine Ariti is taken orally, usually once daily after a meal to improve absorption and reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise instructed by a healthcare professional.

Serious adverse events, though uncommon, include seizures, cardiac arrhythmias, severe allergic reactions, and hallucinations. Patients should seek immediate medical attention if they experience any of these symptoms while on therapy.

Memantine Ariti is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists.